NCT06359379 is a Phase 2 clinical trial of Ropidoxuridine in Glioblastoma, IDH-wildtype, sponsored by Shuttle Pharmaceuticals, Inc..

Who is sponsoring NCT06359379?

NCT06359379 is sponsored by Shuttle Pharmaceuticals, Inc..

What drugs are being tested in NCT06359379?

Interventions in NCT06359379: Ropidoxuridine.

What condition does NCT06359379 study?

NCT06359379 studies Glioblastoma, IDH-wildtype.

Is NCT06359379 still recruiting?

NCT06359379 is currently terminated. Last updated 18 December 2025.

Last reviewed 2025-12-18 · How we verify

NCT06359379

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Terminated Phase 2 Last updated 18 December 2025

What this trial tests

Phase 2 trial testing Ropidoxuridine in Glioblastoma, IDH-wildtype in 30 participants. Terminated before completion.

Timeline

2 September 2024

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	Shuttle Pharmaceuticals, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	2 September 2024
Primary completion	1 December 2025
Estimated completion	1 December 2025
Sites	6 locations across United States

Drugs / interventions tested

Ropidoxuridine — full drug profile →

Conditions studied

Glioblastoma, IDH-wildtype — all drugs for Glioblastoma, IDH-wildtype →

Sponsor

Shuttle Pharmaceuticals, Inc.

Who can join

18 and older, any sex, with Glioblastoma, IDH-wildtype. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, open-label, phase 2 study evaluating the safety and efficacy of oral ropidoxuridine as a radiation-sensitizing agent in patients with newly diagnosed wild-type isocitrate dehydrogenase glioblastoma with an unmethylated O6-methylguanine-DNA methyltransferase promoter, undergoing standard 60 Gy radiotherapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical translation and landscape of stimuli-responsive nanomedicines and microscale therapeutics.
Kobzev D, Kulyk O, Barmin RA, Tatarets A, et al · · 2026 · PMID 42210822 · DOI 10.1039/d6cs00165c
Advancing cancer radiotherapy: Harnessing radiosensitizers and nanotechnology for enhanced tumor control.
Shiridokht F, Kehtari P, Eskandani M, Farajollahi A, et al · · 2025 · PMID 41189671 · DOI 10.1016/j.ijpx.2025.100419

Verify or expand the search:

Other trials of Ropidoxuridine

Trials testing the same drug.

NCT04406857 — Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Ra · Phase 1 · terminated
NCT02993146 — Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases · Phase 1 · active not recruiting
NCT02381561 — Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy · Phase 1 · active not recruiting

Other recruiting trials for Glioblastoma, IDH-wildtype

Currently open trials in the same condition.

NCT06419946 — Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma · Phase 3 · recruiting
NCT06327451 — Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma · Phase 2 · recruiting
NCT06418113 — Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma · Phase 1 · recruiting
NCT05941234 — Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma · NA · recruiting
NCT05929495 — Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06359379 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shuttle Pharmaceuticals, Inc.
Last refreshed: 18 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06359379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing